Publications & Presentations
September 5–9, 2020
A Randomized-Controlled Trial of Tesomet Resulted in Significant Weight Loss in Hypopituitary Patients with Hypothalamic Obesity
Huynh K, Klose M, Krogsgaar K, Drejer J, Byberg S, Madsbad S, Magkos F, Aharaz A, Edsberg B, Astrup A, Feldt-Rasmussen U. Endocrine Abstracts (2020) 70 AEP1073 | DOI: 10.1530/endoabs.70.AEP1073
April 19, 2020
Anti-Tremor Action of Subtype Selective Positive Allosteric Modulators of GABAA Receptors in a Rat Model of Essential Tremors
Amrutkar DV, Dyhring T, Jacobsen TA, Larsen JS, Sandager-Nielsen K. Cerebellum. 2020 Apr;19(2):265-274. doi: 10.1007/s12311-020-01106-w.PMID: 31989440
January 06, 2020
Pharmacology of Small- and Intermediate-Conductance Calcium-Activated Potassium Channels
Brown BM, Shim H, Christophersen P, Wulff H. Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:219-240. doi: 10.1146/annurev-pharmtox-010919-023420. Epub 2019 Jul 23.PMID: 31337271
2019
Tesomet – A New Treatment Opportunity in Prader-Willi Syndrome. Results from Phase 2a Exploratory Studies in Adult and Adolescent Patients
Torok D, Kolouskova S, Walter P, Edsberg B, Dvorak R. International Prader-Willi Syndrome Organization Conference 2019. Abstract on page 47.
November 05, 2012
Anti‐Hypertensive Treatment Preserves Appetite Suppression while Preventing Cardiovascular Adverse Effects of Tesofensine in Rats
Hjorth Bentzen B, Grunnet M, Hyveled‐Nielsen L, Sundgreen C, Buus Lassen J, Hansen H. Obesity. 2012 Nov 5. https://doi.org/10.1002/oby.20122